- Home
- CNF vs DXR Comparison
CNF vs DXR Comparison
Compare CNF & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- DXR
- Stock Information
- Founded
- CNF 1999
- DXR 1970
- Country
- CNF China
- DXR United States
- Employees
- CNF N/A
- DXR N/A
- Industry
- CNF Finance: Consumer Services
- DXR Medical/Dental Instruments
- Sector
- CNF Finance
- DXR Health Care
- Exchange
- CNF Nasdaq
- DXR Nasdaq
- Market Cap
- CNF 35.7M
- DXR 36.4M
- IPO Year
- CNF 2018
- DXR N/A
- Fundamental
- Price
- CNF $0.78
- DXR $9.33
- Analyst Decision
- CNF
- DXR Strong Buy
- Analyst Count
- CNF 0
- DXR 1
- Target Price
- CNF N/A
- DXR $25.00
- AVG Volume (30 Days)
- CNF 201.2K
- DXR 5.6K
- Earning Date
- CNF 08-27-2025
- DXR 01-01-0001
- Dividend Yield
- CNF N/A
- DXR N/A
- EPS Growth
- CNF N/A
- DXR 86.16
- EPS
- CNF 0.08
- DXR 0.11
- Revenue
- CNF $85,661,735.00
- DXR $119,714.00
- Revenue This Year
- CNF $252.34
- DXR N/A
- Revenue Next Year
- CNF N/A
- DXR N/A
- P/E Ratio
- CNF $10.15
- DXR $85.47
- Revenue Growth
- CNF N/A
- DXR N/A
- 52 Week Low
- CNF $0.37
- DXR $6.55
- 52 Week High
- CNF $2.84
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- CNF 61.79
- DXR 52.98
- Support Level
- CNF $0.60
- DXR $8.75
- Resistance Level
- CNF $0.83
- DXR $9.90
- Average True Range (ATR)
- CNF 0.10
- DXR 0.53
- MACD
- CNF 0.02
- DXR -0.08
- Stochastic Oscillator
- CNF 80.09
- DXR 53.28
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.